

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Biological Chemistry

ESPS manuscript NO: 16597

Title: Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis

Reviewer's code: 01482015

Reviewer's country: Taiwan

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-28 17:56

Date reviewed: 2015-02-24 17:31

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The paper is well written and eligible to be published in the journal. The authors stated that this study was supported in part by Abbott Pharmaceutical in the ACKNOWLEDGEMENTS. It is better to describe in detail what kind of support the company give (grant or drug providers?) before acceptance.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Biological Chemistry

ESPS manuscript NO: 16597

Title: Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis

Reviewer's code: 02601681

Reviewer's country: Slovenia

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-28 17:56

Date reviewed: 2015-01-31 17:26

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The paper "EFFECT OF PARICALCITOL AND ENALAPRIL ON RENAL INFLAMMATION AND OXIDATIVE STRESS IN MOUSE MODEL OF ATHEROSCLEROSIS" is very well written research paper. In their study they concluded that paricalcitol and enalapril combination therapy affords protection against renal inflammation and oxidative stress in atherosclerosis. The title is appropriate. The abstract provides a clear delineation between the research background, objectives, materials and methods, results, and conclusions may be derived from the data. Methods, Results and discussion section are well written. Language is appropriate.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Biological Chemistry

ESPS manuscript NO: 16597

Title: Effect of paricalcitol and enalapril on renal inflammation/oxidative stress in atherosclerosis

Reviewer's code: 02621043

Reviewer's country: United States

Science editor: Xue-Mei Gong

Date sent for review: 2015-01-28 17:56

Date reviewed: 2015-02-22 04:58

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input type="checkbox"/> No	

COMMENTS TO AUTHORS

Husain et al. have studied the effects of two drugs, paricalcitol and enalapril, on renal inflammation and oxidative stress in ApoE-deficient atherosclerotic mice. They show that the mice develop hypertension which is prevented by enalapril or enalapril plus paricalcitol treatments but not with paricalcitol alone. In addition, renal inflammation and oxidative damage are shown to be associated with significant alterations in the expression of a set of proteins, such as up-regulation of TNF-alpha and down-regulation of CuZn-SOD. These changes can be significantly reduced by treatment with paricalcitol and enalapril. The work is executed professionally, with due statistical analysis. The manuscript is well written and the data clearly presented. This reviewer has no concerns except for some minor typos or corrections as specified below: Minor corrections: P. 2: Change chemoattractant to chemoattractant P. 5: Change Institute to Institutes P. 6: Change "resolved on 12.5% SDS polyacrylamide gel (SDS PAGE)" to "resolved by 12.5% SDS polyacrylamide gel electrophoresis (SDS PAGE)"